Loading…
Employees: 529
Size Shanghai Xiao Fang Pharmaceutical (603207.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $544M, the 3653rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥22.66 on 6 Nov 2026.
Performance Over six months the shares fell 13.7%, against -10.3% for the median peer and -16.4% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 9.8% over the last twelve months (peer median +7.9%); the operating margin is 39.4% (peer median 8.4%).
Valuation It trades at 5.3× enterprise value to sales against a peer median of 4.7× (10th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 34.7 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥554M | CN¥521M | CN¥471M | CN¥472M | CN¥457M |
| Revenue growth | — | +10% | 0% | +3% | — |
| Gross profit | CN¥335M | CN¥337M | CN¥307M | CN¥308M | CN¥268M |
| EBITDA | n/a | CN¥241M | CN¥237M | CN¥233M | CN¥206M |
| Net income | CN¥193M | CN¥207M | CN¥205M | CN¥204M | CN¥175M |
| Free cash flow | CN¥131M | CN¥111M | CN¥128M | CN¥122M | CN¥78.8M |
| Capital expenditure | CN¥71.7M | CN¥54.2M | CN¥83.9M | CN¥80.2M | CN¥61.6M |
| Total debt | CN¥5.55M | CN¥9.65M | CN¥2.32M | CN¥442,274 | CN¥882,770 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603207.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.9% | -11.6% | 8th highest of 21 |
| 6-month return | -13.7% | -10.3% | 11th highest of 21 |
| Distance from 52-week high | -31.5% | -31.4% | 10th lowest of 21 |
| Revenue growth (TTM) | +9.8% | +7.9% | 10th highest of 21 |
| Operating margin | 39.4% | 8.4% | highest of 19 |
| EV / Sales | 5.3× | 4.7× | 10th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -3.9% | 6.7% | 4th least demanding of 8 |
| Growth delivered (Del g) | +7.6% | +9.6% | 3rd lowest of 8 |
| Hurdle (Req g minus delivered) | -11.5 pp | -14.8 pp | 4th most demanding of 8 |
| ROIC minus cost of capital | +34.7 pp | -2.8 pp | highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | 5.3× | -3.9% | +7.6% |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 1.0× | -12.5% | +11.1% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | 2.4× | -5.2% | +9.6% |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 5.5× | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | 6.8× | n/a | n/a |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | 2.7× | 17.7% | +4.4% |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | 285.6× | n/a | n/a |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | 2.2× | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | 6.5× | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 7.9× | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 2.1× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |